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Chronic kidney disease (CKD) is unique 
among chronic health conditions. In 
addition to the risk of kidney injury in 
the wake of nonrenal organ system dys-
function, the kidneys play a key role in 
the disposition of drugs used in hospi-
talized patients. Moreover, CKD is fre-
quently unrecognized, increasing the 
threat to patient safety. As has been pre-
viously discussed, 1 CKD is frequently 
associated with several comorbidities 
and disease sequelae, which compound 
the risk for harm related either to care 
delivered (to vulnerable patients) or to 
care omitted because of inattention or 
low levels of recognition of CKD 
( Figure 1 ). Patients with CKD are com-
monly exposed to variably informed 
providers, multiple therapeutic interven-
tions, and polypharmacy. Conversely, 
they may have neglected treatment 
needs. Th e convergence of these factors 
increases CKD patients ’ susceptibility to 
patient safety mishaps.
 It is well documented that CKD and 
its associated reduction in glomerular 
fi ltration rate are oft en not detected. 2 
Th e failure to recognize CKD in patients 
who encounter the health-care system 
leaves them at risk for medication errors 
that can exacerbate the severity of their 
illness, prolong hospital stay, and poten-
tially accelerate disease progression. 
A significant proportion of available 
drugs are cleared or metabolized by the 
kidney or can be nephrotoxic. 3 Previous 
studies have documented that many 
medications ordered in the hospital 
have the potential to be nephrotoxic 
or require prescription modification 
in order to be administered safely in 
the CKD population. 4,5 
 Hug  et al. 6 (this issue) set out to exam-
ine the incidence and significance of 
adverse drug events (ADEs) among hos-
pitalized patients with impaired kidney 
function who were sampled from six 
community hospitals in Massachusetts 
from January 2005 to August 2006. Th e 
study sample was drawn from a survey of 
all hospitalized patients admitted to one 
of the six hospitals during the observa-
tion interval. Th e subset of patients with 
a serum creatinine concentration greater 
than 1.5  mg / dl during hospitalization was 
identifi ed, with 150 patients randomly 
selected from each of the six hospitals for 
further chart review. Th e fi nal sample of 
900 charts then underwent abstraction 
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 Patients with chronic kidney disease (CKD) are at increased risk of harm 
as a consequence of errors in medical care. Hug and colleagues highlight 
the significance of adverse drug events in hospitalized patients with 
CKD. Their findings demonstrate the role adverse drug events play in the 
safety of patients with CKD and underscore the importance of novel 
strategies intended to reduce such medical errors. 
 Kidney International (2009)  76, 1123 – 1125.  doi: 10.1038/ki.2009.315 
by trained study nurses to estimate cre-
atinine clearance using the Cockcroft  –
 Gault equation and to identify suspected 
ADEs, which were then reviewed by two 
physicians. Th e physician adjudicators 
determined whether an ADE had 
occurred, which was defi ned here as an 
injury related to a drug. Th e adjudicators 
also determined whether a potential 
ADE was detected, defi ning this as an 
incident that had the potential for injury 
but did not actually lead to one. The 
reviewers graded the severity of each 
event and the likelihood that a given 
event was preventable. Length of hospi-
tal stay and mortality were also recorded 
for each hospitalization. 
 Th e results demonstrated a high rate of 
both ADEs (10.0 per 100 admissions) 
and potential ADEs (55.3 per 100 admis-
sions) in the sampled hospitalized 
patients with elevated serum creatinine 
concentrations. A majority of ADEs and 
potential ADEs were classifi ed as serious 
or signifi cant, and almost 5 % were life-
threatening. Strikingly, while most 
potential ADEs were preventable, almost 
none were intercepted. Likewise, a 
majority of the ADEs were not prevented 
before infl icting injury. Th e most com-
mon drug classes accounting for pre-
ventable ADEs were antibiotics, followed 
by analgesics (37 and 31.5 % of events, 
respectively). Patients with elevated 
serum creatinine concentrations who 
experienced an ADE had, on average, 
a more than 5-day excess length of stay, 
weighted by diagnosis-related group, 
when compared with hospita lized 
patients with elevated serum creati nine 
concentrations who did not have 
an ADE. 
 Th e authors concluded that a majority 
of the medication errors identifi ed could 
have been prevented with appropriate 
drug dose modifications taking into 
account measured changes in kidney 
function. Th ey endorse the use of a com-
puterized physician order entry (CPOE) 
system and discuss the plan for imple-
mentation of such a system statewide. 
Th is study was likely a pre-intervention 
assessment of the baseline rate of medical 
errors in a high-risk population. The 
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linking ADEs and length of hospital stay 
should not be assumed to be unidirec-
tional — leading from the former to the 
latter — as it is quite plausible that longer 
lengths of hospital stay increased the at-
risk time for ADEs. Events were 
expressed per 100 hospital admissions, 
and the latter concern could have been 
addressed by the reporting of rates per 
fi xed unit of hospital days. 
 Although the authors ’ implied con-
clusion that a CPOE system could 
reduce the frequency of medication 
errors and improve the safety of care for 
patients with CKD is reasonable, this 
technology addresses only a part of the 
problem. In an eff ort to reduce medical 
errors, several strategies have been 
developed and implemented to improve 
the quality of care for hospitalized 
patients with and without CKD. For 
instance, the inclusion of a pharmacist 
on hospital rounds has reduced the fre-
quency of medication errors. 10 The 
advent of International Classifi cation of 
Diseases, Ninth Revision, Clinical Mod-
ifi cation (ICD-9-CM) codes specifi c to 
CKD may help to raise awareness of 
non-dialysis-requiring CKD among 
non-nephrologists caring for hospital-
ized patients. Any alert strategies deliver 
the message to only a limited audience 
(the hospital-based health-care team). 
Patients with CKD are subject to medi-
cation errors in other venues, including 
remote hospitals and providers who do 
not have access to their medical infor-
mation and might recognize a patient ’ s 
illness only if they choose to measure 
kidney function. Individuals also 
receive care and medications in ambu-
latory settings such as clinics and 
urgent-care facilities, which might not 
have access to a CPOE system or the 
patient ’ s health information. Similarly, 
patients who acquire over-the-counter 
medications might not consider their 
impaired kidney function when they 
make their purchase. 
 Finally, as  Figure 1 illustrates, medica-
tion errors represent only one dimension 
of patient safety in CKD. Several other 
aspects of the disease can lead to unan-
ticipated harm as a consequence of 
administered or omitted care to this 
complex population. Novel strategies to 
authors assert that such a structural 
intervention has been shown to have an 
impact on medication errors, and they 
cite examples. 7 
 Th e authors should be commended 
for their eff orts to provide a valid esti-
mate of the incidence of ADEs among 
patients with CKD. Th eir sampling in a 
set of community hospitals is notewor-
thy, as prior studies conducted princi-
pally in tertiary-care medical centers 
have limited generalizability. Th eir use 
of the Institute for Healthcare Improve-
ment trigger tool method 8 was an eff ec-
tive way to screen a large number of 
charts and to identify a relatively 
uncommon set of events. Th eir eff ort to 
ensure validity by reporting inter-rater 
reliability is appreciated. Th ey acknowl-
edge limitations to their study, including 
underrepresentation of minority groups 
in the study hospitals and the potential 
for bias due to staff sensitization to 
patient safety related to impending 
implementation of CPOE systems at 
some of the six sites. 
 Additional limitations to consider 
include the use of a single serum creati-
nine determination during hospitaliza-
tion as the index measurement for a 
patient ’ s assignment as  ‘ CKD. ’ Use of two 
or more determinations, and / or consid-
eration of outpatient serum creatinine 
concentrations, would likely reduce mis-
classifi cation and provide more accurate 
estimates of the risk of ADEs in patients 
with true CKD. Use of the abbreviated 
Modifi cation of Diet in Renal Disease 
(MDRD), Mayo quadratic, or Chronic 
Kidney Disease Epidemiology Collabo-
ration (CKD-EPI) equations 9 might 
have been preferred over use of the 
Cockcroft  – Gault equation to estimate 
kidney function in the study subjects; 
however, the latter has been tradition-
ally used by physicians and pharmacists 
in relation to drug dosing in hospital-
ized patients. Also, the causal pathway 
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 Figure 1  |  Chronic kidney disease represents an assembly of several high-risk factors, 
which, under circumstances of poor disease recognition, can lead to adverse patient 
safety events . 
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facilitate CKD recognition across the 
broad landscape of the health-care sys-
tem and to promote the provision of 
CKD-specifi c safe care are lacking and 
should be developed. Nevertheless, the 
findings of Hug  et al. , 6 and their 
 endorsement of the use of CPOE sys-
tems, are important steps toward increas-
ing the medical community ’ s awareness 
of the sensitivity of patients with CKD to 
medication administration and toward 
improving the safety of their care. As 
nephrologists, we should expand beyond 
our traditional  ‘ nephrocentric ’ view of 
the universe. Eff orts to prevent nephro-
toxicity or to slow progression of CKD 
should not be abandoned, but a more 
holistic approach to enhancing patient 
safety should become a priority of our 
collective practice. 
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 Increased oxidative stress, resulting from 
an imbalance between oxidant production 
and antioxidant reserves, is highly preva-
lent in a wide variety of chronic kidney 
diseases (CKD). 1,2 Oxidative, as well as 
carbonyl, stress in uremic states often 
incites damage to biologically important 
macromolecules, including proteins, lip-
ids, carbohydrates, and nucleic acids, and 
causes them to undergo structural modi-
fi cations, which leads to generation of the 
so-called advanced oxidation protein 
products (AOPPs), advanced lipoxidation  
end products, and advanced glycation end 
products. AOPPs are a family of oxidized, 
dityrosine-containing protein products 
generated during excessive production of 
oxidants and oft en carried by albumin 
 in vivo . 3 Accumulation of plasma and 
renal AOPPs is a common pathologic 
fi nding in dialysis patients, as well as in 
patients with diabetes and metabolic syn-
drome. Accordingly, the levels of plasma 
and tissue AOPPs are postulated as a 
reliable marker to estimate the degree 
of oxidant-mediated protein damage in 
uremic patients. 
 Emerging evidence indicates that 
AOPPs may not merely be a surrogate 
marker for oxidative stress in the injured 
kidney; they are actually a new class of 
renal pathogenic mediators as well. 
Clinical studies have shown that AOPP 
level is a strong predictor for the progno-
sis of IgA nephropathy. 4 In experimental 
models, chronic accumulation of plasma 
AOPPs in rats is associated with an 
increase in urinary protein excretion, 
decreased creatinine clearance, exagger-
ated macrophage infi ltration, and aggra-
vated glomerulosclerosis in remnant 
kidney and diabetic nephropathy. 5 Given 
that AOPPs are capable of inducing renal 
expression of proinfl ammatory cytokines 
and activate nuclear factor-  B signaling, 
their detrimental eff ects are oft en thought 
to result from the activation of a redox-
sensitive infl ammatory pathway . Not sur-
prisingly, AOPPs are also implicated in 
the pathogenesis of atherosclerosis and 
cardiovascular disorders in patients with 
chronic renal insuffi  ciency. In fact, AOPPs 
have been identifi ed as an independent 
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 Advanced oxidation protein 
products: a causative link 
between oxidative stress 
and podocyte depletion 
 Youhua  Liu 1   
 Advanced oxidation protein products (AOPPs), a protein biomarker of 
increased oxidative stress, are elevated in uremic patients. Zhou  et al. 
demonstrate that chronic administration of AOPPs induces podocyte 
apoptosis and proteinuria in normal rats via a cascade of signaling 
events. This study for the first time establishes a causative link between 
oxidative stress and podocyte depletion and could have broad 
implications in our understanding of the pathogenic mechanism 
of proteinuria. 
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